Summit Partners Public Asset Management, LLC Ascendis Pharma A/S Put Options Transaction History

Summit Partners Public Asset Management, LLC

$2.79 Billion
Q3 2024

Put Options

2 transactions

Quarter	Operation	Price Per put	puts change	puts Held	SEC Form
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $6.73 Million - $8.54 Million	55,600 Added 74.03%	130,700 $17.8 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $9.27 Million - $12 Million	75,100 New	75,100 $11.4 Million

Others Institutions Holding ASND

# of Institutions

244

Shares Held

58.8M

Call Options Held

250K

Put Options Held

377K

Ra Capital Management, L.P. Boston, MA

9.71M
Shares

$1.28 Billion
20.22% of portfolio
Westfield Capital Management CO LP Boston, MA

5.13M
Shares

$674 Million
3.62% of portfolio
Avoro Capital Advisors LLC New York, NY

4.99M
Shares

$655 Million
11.21% of portfolio
Artisan Partners Limited Partnership Milwaukee, WI

4.41M
Shares

$579 Million
1.03% of portfolio
Janus Henderson Group PLC London, X0

4.19M
Shares

$550 Million
0.33% of portfolio

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.33B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Partners Public Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Summit Partners Public Asset Management, LLC with notifications on news.

Account